3464-15-1

Usage

InChI:InChI=1/C16H13NO2/c18-14-11-16(15(19)17-14,12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10H,11H2,(H,17,18,19)

Upstream product

• 92963-60-5 α,α-diphenylsuccinamic acid 
• 10186-26-2 2,2-diphenylsuccinic acid 
• 134-81-6 benzil 
• 54525-36-9 5-hydroxy-2-oxo-4,5-diphenyl-2,5-dihydro-pyrrole-3-carbonitrile 

Downstream Products

• 5685-20-1 1-methyl-3,3-diphenyl-pyrrolidine-2,5-dione 
• 102796-28-1 5-Hydroxy-4,4-diphenyl-1-(2-vinyl-but-3-enyl)-pyrrolidin-2-one 
• 102796-19-0 5-Hydroxy-4,4-diphenyl-1-(1-vinyl-but-3-enyl)-pyrrolidin-2-one 
• 102796-31-6 (6R,7aS)-6-((E)-3-Hydroxy-propenyl)-1,1-diphenyl-hexahydro-pyrrolizin-3-one 
• 102796-29-2 (6S,7S,8aS)-7-Hydroxy-1,1-diphenyl-6-vinyl-hexahydro-indolizin-3-one 
• 102796-20-3 (5S,7R,8aS)-7-Hydroxy-1,1-diphenyl-5-vinyl-hexahydro-indolizin-3-one 
• 102796-20-3 (5S,7S,8aS)-7-Hydroxy-1,1-diphenyl-5-vinyl-hexahydro-indolizin-3-one 
• 98054-78-5 3,3-diphenyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,5-pyrrolidinedione 
• 1402546-91-1 C₂₈H₂₉N₃O₂ 
• 1402546-92-2 C₂₅H₂₅N₅O₂ 
• 1402546-94-4 C₂₇H₃₃N₃O₂ 
• 1402546-95-5 C₂₂H₂₅N₃O₂ 
• 1402546-96-6 C₂₉H₃₀N₂O₂ 
• 1402546-97-7 C₂₁H₂₂N₂O₃ 

Relevant academic research and scientific papers

AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

The invention relates to novel amidoalkylpiperazinyl derivatives of tricyclic heterocyclic systems of general formula (I), wherein Z represents -NH- and X represents -S-, or Z represents -S- and X represents >C=C1 represents H or -CH3, R6 and R7 both represent H, n is an integer from 0 to 4 inclusive, G represents a cyclic amide or imide moiety, and optical isomers, geometric isomers, and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

Synthesis and anticonvulsant properties of new mannich bases derived from 3,3-disubstituted pyrrolidine-2,5-diones. Part IV

A library of 21 new N-Mannich bases of 3,3-diphenyl- (5a-g), 3-methyl-3-phenyl- (6a-g), and 3-ethyl-3-methylpyrrolidine-2,5-diones (7a-g) were synthesized and evaluated for their anticonvulsant activity in the maximum electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) seizure tests after intraperitoneal injection into mice. The acute neurological toxicity was determined applying the rotarod screen. The results in mice showed that 13 compounds were effective in the MES or/and scPTZ screen. From these, seven molecules were tested in the MES seizures after oral administration in rats. The quantitative studies showed that N-[{4-(2-hydroxyethyl)-piperazin-1-yl}-methyl] -3-methyl-3-phenylpyrrolidine-2,5-dione (6c) and N-[(4-benzylpiperidin-1-yl)- methyl]-3-methyl-3-phenylpyrrolidine-2,5-dione (6f) revealed higher protection in the MES and scPTZ tests than valproic acid or ethosuximide which were used as reference antiepileptic drugs. Four compounds (5c, 6c, 6e, 6f) showed high effectiveness in the 6-Hz psychomotor seizure model of partial and therapy resistant epilepsy.

α,α-Diphenylsuccinimide: Evaluation of anticonvulsant and hydrophobic properties

The anticonvulsant potencies (ED50) of α,α-diphenylsuccinimide, phenytoin, and phenobarbital were evaluated in mice by a standard maximal electroshock technique. Potencies were expressed in terms of intraperitoneal dosage and blood and brain co